79 related articles for article (PubMed ID: 8820952)
1. Clinical reversal of multidrug resistance.
Bates SE; Wilson WH; Fojo AT; Alvarez M; Zhan Z; Regis J; Robey R; Hose C; Monks A; Kang YK; Chabner B
Stem Cells; 1996 Jan; 14(1):56-63. PubMed ID: 8820952
[TBL] [Abstract][Full Text] [Related]
2. Clinical Reversal of Multidrug Resistance.
Bates SE; Wilson WH; Fojo AT; Alvarez M; Zhan Z; Regis J; Robey R; Hose C; Monks A; Kang YK; Chabner B
Oncologist; 1996; 1(4):269-275. PubMed ID: 10388001
[TBL] [Abstract][Full Text] [Related]
3. Controlled trial of dexverapamil, a modulator of multidrug resistance, in lymphomas refractory to EPOCH chemotherapy.
Wilson WH; Bates SE; Fojo A; Bryant G; Zhan Z; Regis J; Wittes RE; Jaffe ES; Steinberg SM; Herdt J
J Clin Oncol; 1995 Aug; 13(8):1995-2004. PubMed ID: 7636540
[TBL] [Abstract][Full Text] [Related]
4. Phase I and pharmacokinetic study of the multidrug resistance modulator dexverapamil with EPOCH chemotherapy.
Wilson WH; Jamis-Dow C; Bryant G; Balis FM; Klecker RW; Bates SE; Chabner BA; Steinberg SM; Kohler DR; Wittes RE
J Clin Oncol; 1995 Aug; 13(8):1985-94. PubMed ID: 7636539
[TBL] [Abstract][Full Text] [Related]
5. A multicenter trial of infusional etoposide, doxorubicin, and vincristine with cyclophosphamide and prednisone (EPOCH) in patients with relapsed non-Hodgkin's lymphoma.
Wilder DD; Ogden JL; Jain VK
Clin Lymphoma; 2001 Mar; 1(4):285-92. PubMed ID: 11707843
[TBL] [Abstract][Full Text] [Related]
6. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of dexverapamil plus anthracycline in patients with metastatic breast cancer who have progressed on the same anthracycline regimen.
Warner E; Hedley D; Andrulis I; Myers R; Trudeau M; Warr D; Pritchard KI; Blackstein M; Goss PE; Franssen E; Roche K; Knight S; Webster S; Fraser RA; Oldfield S; Hill W; Kates R
Clin Cancer Res; 1998 Jun; 4(6):1451-7. PubMed ID: 9626462
[TBL] [Abstract][Full Text] [Related]
8. P-glycoprotein expression in non-Hodgkin's lymphomas of human immunodeficiency virus infected patients.
Tanaka PY; Calore EE
Pathol Res Pract; 2007; 203(1):1-7. PubMed ID: 17157997
[TBL] [Abstract][Full Text] [Related]
9. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
10. A prospective, non-randomised phase 1-2 trial of VACOP-B with filgrastim support for HIV-related non-Hodgkin's lymphoma.
Sawka CA; Shepherd FA; Franssen E; Brandwein J; Dotten DA; Routy JP; Walker IR; St-Louis J; Taylor M; Arts K; Crump M; Foote M
Biotechnol Annu Rev; 2005; 11():381-9. PubMed ID: 16216784
[TBL] [Abstract][Full Text] [Related]
11. 14-day variant of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone regimen in advanced-stage Hodgkin's lymphoma: results of a pilot study of the German Hodgkin's Lymphoma Study Group.
Sieber M; Bredenfeld H; Josting A; Reineke T; Rueffer U; Koch T; Naumann R; Boissevain F; Koch P; Worst P; Soekler M; Eich H; Müller-Hermelink HK; Franklin J; Paulus U; Wolf J; Engert A; Diehl V;
J Clin Oncol; 2003 May; 21(9):1734-9. PubMed ID: 12721249
[TBL] [Abstract][Full Text] [Related]
12. [EPOCH therapy for relapsed/refractory lymphoid malignancies].
Dobashi N; Usui N; Kobayashi T; Yamazaki H; Asai O; Yano S; Kato A; Watanabe H; Nagamine M; Katori M; Tajima N; Kuraishi Y
Rinsho Ketsueki; 1998 Apr; 39(4):267-72. PubMed ID: 9597893
[TBL] [Abstract][Full Text] [Related]
13. [Survival of patients with aggressive non-hodgkin's lymphoma: no difference between first line treatment in a prospective randomised phase III clinical trial and first line treatment according to routine clinical practice].
van Agthoven M; Wittebol S; Budel LM; Uyl-de Groot CA; Kramer MH
Ned Tijdschr Geneeskd; 2004 Jan; 148(2):88-93. PubMed ID: 14753131
[TBL] [Abstract][Full Text] [Related]
14. Salvage radiotherapy in patients with relapsed and refractory Hodgkin's lymphoma: a retrospective analysis from the German Hodgkin Lymphoma Study Group.
Josting A; Nogová L; Franklin J; Glossmann JP; Eich HT; Sieber M; Schober T; Boettcher HD; Schulz U; Müller RP; Diehl V; Engert A
J Clin Oncol; 2005 Mar; 23(7):1522-9. PubMed ID: 15632410
[TBL] [Abstract][Full Text] [Related]
15. Liposome-encapsulated doxorubicin in combination with standard agents (cyclophosphamide, vincristine, prednisone) in patients with newly diagnosed AIDS-related non-Hodgkin's lymphoma: results of therapy and correlates of response.
Levine AM; Tulpule A; Espina B; Sherrod A; Boswell WD; Lieberman RD; Nathwani BN; Welles L
J Clin Oncol; 2004 Jul; 22(13):2662-70. PubMed ID: 15226333
[TBL] [Abstract][Full Text] [Related]
16. Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin's Lymphoma Study Group.
Behringer K; Breuer K; Reineke T; May M; Nogova L; Klimm B; Schmitz T; Wildt L; Diehl V; Engert A;
J Clin Oncol; 2005 Oct; 23(30):7555-64. PubMed ID: 16234521
[TBL] [Abstract][Full Text] [Related]
17. Modulation of multidrug resistance by dexverapamil in EPOCH-refractory lymphomas.
Wilson WH; Bates SE; Fojo A; Chabner BA
J Cancer Res Clin Oncol; 1995; 121 Suppl 3():R25-9. PubMed ID: 8698739
[TBL] [Abstract][Full Text] [Related]
18. Chemotherapy with etoposide, vincristine, doxorubicin, bolus cyclophosphamide, and oral prednisone in patients with refractory cutaneous T-cell lymphoma.
Akpek G; Koh HK; Bogen S; O'Hara C; Foss FM
Cancer; 1999 Oct; 86(7):1368-76. PubMed ID: 10506727
[TBL] [Abstract][Full Text] [Related]
19. Plasma glutathione S-Transferase P1-1 as a prognostic factor in patients with advanced non-Hodgkin's lymphoma (stages III and IV).
Katahira T; Takayama T; Miyanishi K; Hayashi T; Ikeda T; Takahashi Y; Takimoto R; Matsunaga T; Kato J; Niitsu Y
Clin Cancer Res; 2004 Dec; 10(23):7934-40. PubMed ID: 15585627
[TBL] [Abstract][Full Text] [Related]
20. Long-term follow-up of a prospective study of combined modality therapy for stage I-II indolent non-Hodgkin's lymphoma.
Seymour JF; Pro B; Fuller LM; Manning JT; Hagemeister FB; Romaguera J; Rodriguez MA; Ha CS; Smith TL; Ayala A; Hess M; Cox JD; Cabanillas F; McLaughlin P
J Clin Oncol; 2003 Jun; 21(11):2115-22. PubMed ID: 12775737
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]